Vice President, Asset Strategy Lead
Syndax Pharmaceuticals
August 11, 2026
On-site
New York, NY
Corporate Functions
The Asset Strategy Lead (ASL), Late Development provides leadership to a cross-functional strategic asset team and leads the development and execution of the asset strategy. Champions the product/brand at all levels and manages alignment on Asset Strategy Team (AST) communication.
Key Responsibilities:
- Provide strategic leadership for a late-stage, commercially approved asset with an ongoing Phase 3 program; ensure integration across clinical development, regulatory, and commercial lifecycle priorities.
- Lead design and execution of a differentiated external strategy focused on investigator-sponsored research (ISR), peer-to-peer scientific engagement, and academic collaboration.
- Build and sustain relationships with key investigators, institutions, and thought leaders.
- Serve as an external ambassador at scientific congresses, advisory boards, and strategic forums.
- Identify potential issues; lead contingency planning; drive AST problem solving and decision-making.
- Liaise with the Executive Leadership Team with updates, insights, and recommendations.
- Lead long-range planning (scenario planning, investment strategy, external innovation assessments).
- Partner with Commercial, Medical Affairs, Regulatory, and Development to shape Target Product Profile (TPP) and lifecycle/global expansion planning.
- Lead resolution of conflict at the AST and oversee governance engagement.
- Foster a culture of accountability, innovation, and excellence.
- Represent the company in strategic partnerships and scientific/medical forums.
Desired Experience/Education and Personal Attributes:
- Advanced degree (PhD, MD, MBA) highly preferred.
- 10+ years in late-stage development; ideally an approved asset and active Phase 3 or lifecycle expansion.
- Track record operating across development, medical affairs, and commercial functions; experience in Medical Affairs, Commercial, or Market Access strongly preferred.
- Strong business acumen and ability to evaluate clinical strategy commercially.
- Experience translating scientific/clinical data into product narratives for launch and lifecycle growth.
- Ability to partner to shape TPP and align evidence generation with market needs.
- Deep understanding of post-approval evidence generation (ISR, RWE, publication planning).
- Experience interacting with C-suite executives, external partners, and regulators.
- Highly collaborative with strong influencing skills; executive presence and communication skills.
- Portfolio management, financial modeling, and program valuation highly desirable.
Key Responsibilities:
- Provide strategic leadership for a late-stage, commercially approved asset with an ongoing Phase 3 program; ensure integration across clinical development, regulatory, and commercial lifecycle priorities.
- Lead design and execution of a differentiated external strategy focused on investigator-sponsored research (ISR), peer-to-peer scientific engagement, and academic collaboration.
- Build and sustain relationships with key investigators, institutions, and thought leaders.
- Serve as an external ambassador at scientific congresses, advisory boards, and strategic forums.
- Identify potential issues; lead contingency planning; drive AST problem solving and decision-making.
- Liaise with the Executive Leadership Team with updates, insights, and recommendations.
- Lead long-range planning (scenario planning, investment strategy, external innovation assessments).
- Partner with Commercial, Medical Affairs, Regulatory, and Development to shape Target Product Profile (TPP) and lifecycle/global expansion planning.
- Lead resolution of conflict at the AST and oversee governance engagement.
- Foster a culture of accountability, innovation, and excellence.
- Represent the company in strategic partnerships and scientific/medical forums.
Desired Experience/Education and Personal Attributes:
- Advanced degree (PhD, MD, MBA) highly preferred.
- 10+ years in late-stage development; ideally an approved asset and active Phase 3 or lifecycle expansion.
- Track record operating across development, medical affairs, and commercial functions; experience in Medical Affairs, Commercial, or Market Access strongly preferred.
- Strong business acumen and ability to evaluate clinical strategy commercially.
- Experience translating scientific/clinical data into product narratives for launch and lifecycle growth.
- Ability to partner to shape TPP and align evidence generation with market needs.
- Deep understanding of post-approval evidence generation (ISR, RWE, publication planning).
- Experience interacting with C-suite executives, external partners, and regulators.
- Highly collaborative with strong influencing skills; executive presence and communication skills.
- Portfolio management, financial modeling, and program valuation highly desirable.